System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Timon Vandamme is an expert in Oncology at Antwerp University Hospital (Belgium). As of October 2026, ScienceLeadR ranks Timon Vandamme in the top 1% of experts worldwide for Carcinoma. Timon Vandamme has authored 92 publications, the most recent in 2026, and is an investigator in 35 clinical trials, 24 of them ongoing. SLR score: 982 (community average: 125). How the SLR is computed.

LeadR Profile

Timon Vandamme Antwerp University Hospital Belgium
982 ScienceLeadR Reputation 982

Unlock

Register Login
Network Map

Oncology

Subspecialties: Endocrinology - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2012 - 2026
Source: PubMed

University of Antwerp

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 92

Citations

Citations: 1 181 1st author: 6 Last author: 13 Unique author: 0

Main journals

Acta Gastroenterol Belg 6
Ann Oncol 6
ESMO Open 5
J Neuroendocrinol 5
BMC Cancer 4

Best Journals

Ann Oncol 4
J Clin Oncol 2
Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Attitudes of cancer patients toward ctDNA-based liquid biopsy for follow-up.
PMID 42905048 — mental recall, neoplasms, biopsy, therapeutics, liquid biopsy		Mol Oncol20260
Belgian protocol for indication and selection of patients with unresectable colorectal cancer liver metastases eligible for liver transplantation.
PMID 42872337 — liver transplantation, neoplasms, liver, liver neoplasms, neoplasm metastasis, work, transplants, therapeutics, colorectal neoplasms, transplantation		Acta Gastroenterol Belg20260
Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study.
PMID 42629972 — biliary tract neoplasms, neoplasms, cohort studies, survival analysis, biliary tract, gallbladder neoplasms, therapeutics, mutation, cholangiocarcinoma		Int J Cancer20260
Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.
PMID 42407299 — dna mismatch repair, microsatellite repeats, neoplasms, neoadjuvant therapy, rectal neoplasms, therapeutics, microsatellite instability		Eur J Cancer20260
Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
PMID 42288752 — quality of life, lung, neoplasms, everolimus, neuroendocrine tumors, thymus gland		BMC Cancer20260

Clinical Studies 35

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 8

By phase:

Phase 3 12
N/A 10
Phase 2 5
Phase 2/Phase 3 4
Phase 1 2
Phase 1/Phase 2 1
Phase 4 1

By status:

Recruiting 23
Completed 7
Not yet recruiting 3
Unknown 2

By type:

Interventional 33
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 4
multicentric5to9 6
multicentricup10 22

Main Topics

Ongoing Clinical Trials

24 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with IV Bevacizumab Compared to Standard of Care IV Bevacizumab in combination with Oral Trifluridine and Tipiracil in Adult Participants with Refractory Metastatic Colorectal Cancer
2025-521712-19-00 — trifluridine, neoplasms, bevacizumab, colorectal neoplasms		Phase 3Not yet recruiting2026
Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal cancer a multicentre open label randomised pragmatic clinical trial
2023-506703-26-00 — safety, neoplasms, neoadjuvant therapy, rectal neoplasms, therapeutics		Phase 3Recruiting2024
A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with standard chemotherapy
2025-523869-22-00 — neoplasms, multiple chronic conditions, drug therapy, therapeutics, etoposide, carboplatin, carcinoma, neuroendocrine, chemotherapy, carcinoma		Phase 3Recruiting2026
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
2024-519875-24-00 — safety, neoplasms, neuroendocrine tumors, carcinoid tumor		Phase 3Not yet recruiting2025
177Lu edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus
2022-502154-13-00 — lung, somatostatin, safety, neoplasms, everolimus, neuroendocrine tumors, receptors, somatostatin, patient reported outcome measures, thymus gland, therapeutics, receptors, peptide		Phase 3Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS